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INCELL AAFA
TM, an omega-3 polyunsaturated fatty acid product containing a high concentration of long chain fatty acids, was
tested for its ability to ameliorate the harmful side effects of CPT-11 chemotherapy including: leukopenia, anaemia, asthenia,
weight loss and liver involvement. Four groups of mice were fed an AIN-76 diet modiﬁed to contain: 10% w/w corn oil (CO),
0% AAFA
TM; 9% CO, 1% AAFA
TM; 8% CO, 2% AAFA
TM; or 7% CO, 3% AAFA
TM. After 2 weeks on the diets, half of the
mice received CPT-11 chemotherapy (60 mg kg
71 q 4 days, i.v.) the rest of the mice received vehicle for 2 weeks. It was
found that 2% AAFA
TM in the diet of the CPT-11 treated mice: decreased apoptotic ﬁgures in the duodenal crypts; markedly
suppressed the inﬂammatory eicosanoid, prostaglandin E2 in the liver; prevented liver hypertrophy; improved white blood cell
counts; signiﬁcantly increased red blood cell counts; decreased numbers of CPT-11 induced immature red blood cell and
micronuclei in red blood cells of the peripheral blood; increased eicosapentaenoic acid and docosahexaenoic acid in liver cell
membranes and maintained normal grooming behaviour. Thus 2% AAFA
TM in the diet reduced the side effects of CPT-11
treatment in mice.
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We have reported that supplementing the diet of mice with ﬁsh oil
increased the efﬁcacy of edelfosine against MDA-MB 231 human
breast cancer (Hardman et al, 1997), doxorubicin against A549
human lung cancer (Hardman et al, 2000) and CPT-11 against
MCF-7 human breast cancer (Hardman et al, 1999a). Other investi-
gators have found that supplementing the diet with omega-3 fatty
acids increased the efﬁcacy of: epirubicin against rat mammary
tumours (Germain et al, 1999) and cyclophosphamide (Shao et al,
1997) or mitomycin (Shao et al, 1995) against MX-1 human
mammary tumours. The results of in vitro studies have shown that
a small amount of either eicosapentaenoic acid (EPA) or of docosa-
hexaenoic acid (DHA), the major long chain polyunsaturated fatty
acids (PUFAs) found in ﬁsh oil, added to cell culture media can cause
tumour cell death but not kill cultured normal cells (de Vries and Van
Noorden, 1992). Other reported beneﬁts of omega-3 PUFA dietary
supplements given prior to or during cancer therapy include: rever-
sing tumour cell drug resistance (Das et al, 1998), reducing the
gastrointestinal, haematological or cardiac side effects of various
chemotherapeutic treatments (Hardman et al, 1999a; Germain et
al, 1999; Shao et al, 1997), decreasing cancer cachexia (Karmali,
1996; Tisdale, 1993; Barber et al, 1999), and protection from alopecia
(Takahata et al, 1999). Thus supplementing the diet with omega-3
fatty acids may be beneﬁcial during cancer chemotherapy.
However, in past studies, the amount of ﬁsh oil used in the
mouse diets (usually 10 to 20% w/w of the diet though 3% w/w
was used in one study (Hardman et al, 1999a)) was higher than
humans can easily consume. In an effort to reduce the volume
of omega-3 fatty acid supplement required for beneﬁt during
cancer chemotherapy, we have recently acquired INCELL AAFA
TM,
an omega-3 product containing a total of 55% eicosapentaenoic
acid (EPA) + docosahexanoic acid (DHA). We calculated that
between 2 and 3% w/w AAFA
TM in the diet would contain the
same amount of EPA + DHA as in a diet containing 6% ﬁsh oil
thus a smaller volume of AAFA
TM than of ﬁsh oil would be needed
to obtain the beneﬁcial effects of an omega-3 supplement.
We have previously reported that 3 or 6% w/w ﬁsh oil in the diet
increased the efﬁcacy of the CPT-11 against the tumour and
suppressed some of the side effects of CPT-11 treatment (Hardman
et al, 1999a). The topoisomerase inhibitor, CPT-11 has been a very
effective chemotherapeutic drug, however, its use in patients is
limited due to the severe side effects, especially to the intestines
and to the bone marrow (Rothenberg, 1998; Rivory, 1996). Prior to
performing an expensive tumour efﬁcacy study, we wanted to deter-
mine whether a very small amount of AAFA
TM (1 to 3% w/w of the
diet) would lessen the side effects of CPT-11. Since this is a new
product, the speciﬁc aims of this study were: (1) to determine if
signiﬁcant toxicity was associated with consumption of AAFA
TM at
levels of 1, 2 or 3% of the diet in Swiss mice; and (2) to conduct a
detailed study of the side effects of CPT-11 if 0, 1, 2 or 3% INCELL
AAFA
TM was incorporated in a diet containing a total of 10% fat.
MATERIALS AND METHODS
Diet preparation
Dry ingredients were measured and mixed well in bulk, then oil
was thoroughly blended in at 10% of the weight of an aliquot of
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100 g without water): total oil, 10; sugar, 47.4; casein, 18.9; corn-
starch, 14.2; AIN-76 vitamin mix, 0.97; AIN-76 mineral mix,
3.38; choline bitartrate, 0.18; DL-methionine, 0.27; cellulose, 4.7.
Water was added as needed to hold ingredients together, food
was compressed into a ﬂat pan and cut into daily portions for each
cage. Food was stored in air tight containers at 7208C until fed to
the mice. Mice were fed fresh food and old food was removed from
the cage every afternoon, 7 days per week.
Drug preparation
CPT-11 was obtained as irinotecan hydrochloride (Pharmacia &
Upjohn, Kalamazoo, MI, USA). It was prepared, according to the
manufacturer’s directions, to duplicate the clinical formulation
(Camptosar
TM). The prepared CPT-11 contained: 20 mg ml
71
irinotecan hydrochloride, 45 mg ml
71 sorbitol (Sigma, St. Louis,
MO, USA) and 0.9 mg ml
71 lactic acid (Sigma, St. Louis, MO,
USA) and was pH adjusted to 3–3.8. The solution was warmed
in a 1008C water bath to dissolve the CPT-11. A dose of 60 mg
CPT-11 per kg body weight (about 0.08 ml per 28 g mouse) was
injected into the lateral tail vein of each treated mouse, once every
4 days for 2 weeks. We have shown this dose to effectively suppress
the growth of lung, colon and breast cancer xenografts (Hardman
et al, 1999b) and that the efﬁcacy of this dose was increased by
supplementing the diet of xenograft bearing mice with ﬁsh oil
(Hardman et al, 1999a).
Experimental design
The experimental protocol was approved by the The University of
Texas Health Science Center at San Antonio Institutional Animal
Care and Use Committee. The UTHSCSA, as an institution
conducting research, teaching, and education using laboratory
animals, adheres to United States Federal regulations as published
in the Animal Welfare Act (AWA); the Guide for the Care and Use
of Laboratory Animals (Guide); the Public Health Service Policy;
and the US Government Principles Regarding the Care and Use
of Animals. This research meets all guidelines of the United King-
dom Co-ordinating Committee on Cancer Research guidelines for
the welfare of animals in experimental neoplasia (Workman et al,
1998).
Forty male Swiss mice, 6 weeks old, were obtained and ears were
marked for unique identiﬁcation. Mice were housed ﬁve per cage
in UTHSCSA Laboratory Animal Resources facilities. After 24 h
acclimatisation, mice were weighed and the food was changed to
one of four deﬁned diets. The AIN-76 based, 10% total fat diets
are deﬁned above. Ten mice were designated to consume each diet.
All mice were weighed three times weekly throughout the experi-
ment.
Mice consumed the diet for 2 weeks prior to initiation of
chemotherapy with CPT-11. Treatment with CPT-11 was initiated
for half of the mice (one cage of ﬁve mice) on each diet and was
administered at 60 mg kg
71 body weight, i.v. in a lateral tail vein,
once every fourth day for 2 weeks. Control mice received an
equivalent volume of the CPT-11 vehicle.
Mice were killed 24 h after the last CPT-11 treatment. At
necropsy, mice were weighed, anaesthesised and blood was drawn
via cardiac puncture. The liver and duodenum were removed,
weighed then part was ﬁxed in Omniﬁx
1 and part was quick
frozen in liquid nitrogen for later analyses. The ﬁxed duodenum
was oriented in cassettes then processed to parafﬁn blocks. Parafﬁn
sections were cut 4 mm thick, histological slides of the duodenum
were prepared and stained with H&E. Only complete midaxially
sectioned crypts on H&E stained slides of duodenum were selected
for analyses of crypt height and number of apoptotic ﬁgures.
Apoptotic events were identiﬁed by the morphological parameters
of condensation and marginalisation of the nuclear chromatin, cell
shrinking, and fragmentation of the cell into apoptotic bodies, as
previously reported (Hardman et al, 1999a).
Blood counts
The peripheral blood specimen was placed in an EDTA containing
tube and sent to Laboratory Animal Resources for complete blood
counts using a Cell-Dyn 3500R blood analyser with veterinary pack.
Micronuclei and PCE counts
Micronuclei and polychromatophilic erythrocytes (PCE) were iden-
tiﬁed on acridine orange stained smears of peripheral blood, as
previously reported (Vijayalaxmi et al, 1997). Fields containing a
single layer of erythrocytes were identiﬁed. At least eight ﬁelds
containing a total of 3000 to 4000 cells were identiﬁed on each
slide and the number of micronuclei and PCEs were counted
and recorded.
Gas chromatography
Gas chromatography (as previously published (Hardman et al,
2001)) was used to illustrate the incorporation of diet speciﬁc fatty
acids into the mitochondrial and microsomal membranes of liver
of mice that consumed the 0% AAFA
TM and the 2% AAFA
TM diet.
The fatty acid methyl esters were reported as the per cent of the
total methylated fatty acids (area under the curve). There were
no signiﬁcant differences in the lipid content of the microsomal
and mitochondrial fractions of each specimen so mean membrane
fatty acids are reported to illustrate that n-3 PUFAs were incorpo-
rated into the membranes of the liver of mice that consumed 2%
AAFA
TM.
PGE2 assay
The bicyclo-PGE2 enzyme immunoassay kit (Cayman Chemical,
Ann Arbor, MI, USA) was used according to the manufacturer’s
instructions to assay PGE2 in liver homogenates. This kit measures
both PGE2 and the metabolites of PGE2 in tissues and plasma.
Since PGE2 is quickly metabolised, the bicyclo-assay provides a
more reliable estimate of total PGE2 in samples than assay of
PGE2 alone.
Coat quality as a behavioural measure of well-being
Since animals cannot be questioned for how well they feel, beha-
vioural measures can be used as surrogates. One such measure is
coat quality as a reﬂection of normal healthy grooming behaviour.
Comparative evaluation of shiny, clean, well-groomed coats vs
scruffy, matted coats was done by daily observation with results
documented by photography. Each group of mice was lined up
for a picture during the time that the mice were anaesthetised
for their last CPT-11 injection. The appearance of the mice was
documented using a Kodak MDS-120 digital camera and Polaroid
Photo Max software. Digital images were saved, converted to gray-
scale and the composite picture was made using PowerPoint.
Statistical analyses
Most data was analysed by two-way analysis of variance (ANOVA)
to determine main effects due to CPT-11 treatment or to AAFA
TM
consumption then by one-way ANOVA followed by Student-
Newman-Keuls multiple range test to determine differences
between individual groups. The results of two-way ANOVA tells
us whether across both CPT-11 treated and untreated groups, the
consumption of AAFA
TM signiﬁcantly altered a parameter (main
effect due to AAFA
TM) or whether, across all diet groups, CPT-
11 treatment signiﬁcantly altered a parameter (main effect due to
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text below. One-way ANOVA data is presented graphically (Figure
1), the Y-axis of each graph is labelled to identify each set of data.
The results of one-way ANOVA tells us which individual groups
are signiﬁcantly different. On each graph, groups which do not
share a superscript are signiﬁcantly different (P50.05). Linear
regression analyses were used to determine the correlation between
liver mass and liver PGE2.
RESULTS
Figure 1 is a composite of graphs showing the data. There were ﬁve
mice in each group.
Apoptotic ﬁgures and crypt height in the duodenum
(graph 1)
The number of apoptotic cells found in 10 complete, midaxially
sectioned duodenum crypts of each mouse was counted as an indica-
tion of intestinal damage. The results of two-way ANOVA revealed
that CPT-11 treatment signiﬁcantly increased the number of apopto-
tic cells in the duodenum crypts and that consumption of AAFA
TM
signiﬁcantly decreased the number of apoptotic ﬁgures in the duode-
num. Count of the number of cells in each crypt column revealed that
there were no signiﬁcant differences in number of cells in the crypt
column (data not shown) due to consumption of AAFA
TM.
Liver weight (graph 2)
The weight of the liver was expressed as a percentage of the body
weight. Two-way ANOVA revealed that CPT-11 treatment signiﬁ-
cantly increased liver weight and that consumption of AAFA
TM
signiﬁcantly decreased liver weight. The mean liver weights of the
2 or 3% AAFA
TM fed/CPT-11 treated mice were not signiﬁcantly
different from the mean liver weights of the mice that were not
treated with CPT-11.
PGE2 level in the liver (graph 3)
Due to specimen limitations, we were only able to assay PGE2 in
mice that consumed 0 and 2% AAFA
TM, with and without CPT-
11 treatment. Two-way ANOVA revealed that treatment with
CPT-11 increased liver PGE2 and that consumption of 2%
AAFA
TM signiﬁcantly decreased liver PGE2.
Correlation between liver weight and PGE2 content
(graph 4)
Linear regression analysis illustrated the signiﬁcant (r=0.882,
P50.0001) linear relationship between liver mass and liver PGE2.
Blood counts (graphs 5 and 6)
Treatment with CPT-11 signiﬁcantly decreased both red and white
blood cell counts in mice that did not consume AAFA
TM.
However, consumption of AAFA
TM prior to and during CPT-11
treatment was associated with signiﬁcantly higher red blood cell
(RBC) counts and a trend (non-signiﬁcant) to higher white blood
cell (WBC) counts than in mice which did not consume AAFA
TM.
The WBC and RBC counts of 2% AAFA
TM fed/CPT-11 treated
mice were not signiﬁcantly different from those parameters in mice
which did not receive CPT-11.
Micronuclei and polychromataphilic erythrocytes
(graphs 7 and 8)
Micronuclei are formed from broken strands of DNA and poly-
chromataphilic erythrocytes (PCE) are immature erythrocytes.
The results of two-way ANOVA revealed that treatment with
CPT-11 signiﬁcantly increased both micronuclei and PCE counts
and that consumption of 2 or 3% AAFA
TM prior to and during
CPT-11 treatment signiﬁcantly decreased micronuclei and PCE
counts.
Liver membrane fatty acids
As expected, consumption of AAFA
TM increased the EPA and DHA
in liver cellular membranes (expressed as a per cent of the total
lipid in cellular membranes). In mice fed the 10% CO diet, the
EPA and DHA fractions (mean+s.e.) were: EPA=0.08+0.06%
and DHA=0.57+0.27%. In mice fed the 2% AAFA
TM/8% CO diet
the EPA and DHA were signiﬁcantly (P50.01) increased to
EPA=4.5+1.5% and DHA=3.92+0.30%. The fraction of arachi-
donic acid (range 8–10%) in cellular membranes was not signiﬁ-
cantly different due to the diet of the mice.
Coat quality
Figure 2 is a photographic composite of groups of mice that
consumed the ‘normal’ 10% CO diet and that were not treated
with CPT-11 (normal control group) and the groups of CPT-11
treated mice that consumed each of the diets. The coats of the mice
that were treated with CPT-11 but that did not consume AAFA
TM
look ‘scruffy’, i.e., the fur was not smooth and strands of hair were
stuck together, especially in the area between the scapulae.
However, the coats of mice treated with CPT-11 that consumed
1% AAFA
TM look smoother and the coats of mice that consumed
2 or 3% AAFA
TM did not look different from the mice that did not
receive CPT-11.
Body weight
There were no signiﬁcant differences in the mean body weights of
the groups of mice at the beginning of CPT-11 treatment or at the
time of necropsy (data not shown).
DISCUSSION
In humans, late onset diarrhea (424 h post CPT-11 treatment)
associated with intestinal damage and decreased white blood cell
counts, especially decreased neutrophil counts, are the main dose
limiting side effects of treatment with CPT-11 (Rivory, 1996;
Rothenberg et al, 1996, 1999; Rothenberg, 1998). Although the
mouse model used did not develop diarrhea from the CPT-11
treatment, mice have demonstrated malabsorption of water in
the ileum and cecum (Ikuno et al, 1995) following CPT-11 treat-
ment. The intestinal data indicate that consumption of AAFA
TM
prior to and during CPT-11 treatment reduced intestinal damage,
as reﬂected by less CPT-11 induced apoptosis in the crypts of
the small intestine. The decrease in the number of apoptotic ﬁgures
per crypt in CPT-11 treated mice fed 3% AAFA
TM suggest that
omega-3 polyunsaturated fatty acids have a role in protection of
the intestine from genomic damage resulting in programmed cell
death. This result provides evidence in support of a previous claim
that supplementing the diet with omega-3 fatty acids protects
against CPT-11 induced intestinal damage (Hardman et al, 1999a).
The CPT-11 induced enlargement of the livers of mice not fed
AAFA
TM could be due to damage to the liver resulting in inﬂam-
mation, or to hypertrophy as a result of an increased demand to
detoxify blood. Following CPT-11 treatment, humans exhibit
increased serum glutamic oxalic transaminase levels (Rothenberg
et al, 1996) and increased serum bilirubin (Murray and Kelly,
2001) indicating hepatotoxic damage. Drug induced toxic injury
to the liver can produce inﬂammation (Damjanov and Linder,
1996). Thus, inﬂammation induced swelling is a likely cause for
the increased liver weight. Consumption of 2% AAFA
TM reduced
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Figure 1 Graphs 1 to 3 and 5 to 8 illustrate the results of one-way analysis of variance of the data followed by Student–Newman–Keuls multiple range
tests as appropriate. The mean+s.e.m. of ﬁve mice in each group is presented graphically, the Y-axis of each graph is labelled to identify each set of data. On
graphs 1 to 3 and 5 to 8 groups that do not share a capital letter are signiﬁcantly different (P50.05). Graph 4 shows the linear regression analysis (n=15,
r=0.882, slope is signiﬁcantly different from 0, P50.0001) of liver weight and liver PGE2 of individual mice which consumed either 0 or 2% AAFA
TM.
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between a decreased level of the inﬂammatory eicosanoid, PGE2,i n
the liver and by the lack of liver hypertrophy.
The ability of AAFA
TM consumed in the diet to signiﬁcantly
reduce liver PGE2 suggests that the production of inﬂammatory
eicosanoids in the intestine may also be reduced. CPT-11 asso-
ciated intestinal damage is mediated by excess eicosanoid
production (Kase et al, 1997; Sakai et al, 1995, 1997). Thus,
systemic suppression of eicosanoid production by consumption
of omega-3 fatty acids may explain the reduced apoptosis in the
duodenum seen in this study and the reduced intestinal damage
reported in our previous study (Hardman et al, 1999b). More
research is needed to establish the mechanism(s) involved.
Data from human studies indicate that neutropenia and/or
anaemia occurred in 43% of patients treated with CPT-11 (Rothen-
berg et al, 1999). In mice that did not consume AAFA
TM,
treatment with CPT-11 caused a signiﬁcant reduction in the
WBC count and RBC count. However, the data from this study
indicate that consumption of 2% AAFA
TM by mice prior to and
during CPT-11 treatment resulted in RBC counts that were not
signiﬁcantly different from normal and in improved WBC counts.
Eighty-three per cent of humans also report asthenia (tiredness
or weakness) as a side-effect of CPT-11 treatment (Rothenberg et
al, 1999). In mice, asthenia could be demonstrated by behavioural
changes such as lack of grooming. Thus, the ‘scruffy’ look of the
mice that did not consume AAFA
TM and that were treated with
CPT-11 is likely due to this behavioural change. The ‘scruffy’ look
was decreased in mice that consumed 1% AAFA
TM and was
completely eliminated in mice that consumed 2 or 3% AAFA
TM
suggesting that the mice treated with CPT-11 and fed AAFA
TM felt
better and continued normal grooming behaviour.
Micronuclei in the peripheral blood erythrocytes and apoptotic
ﬁgures in the duodenal crypts were used as assays of genomic
damage. Micronuclei are formed in blood cells following double-
strand breaks in DNA resulting in chromosomal fragments left
behind at mitosis (Vijayalaxmi et al, 1997). Apoptosis can result
following unrepaired DNA strand breaks (Potten, 1992). CPT-11
binds to topoisomerase I and stabilises the topoisomerase I induced
DNA strand breaks, leading to irreversible breaks in double-strand
DNA in replicating cells (Slichenmeyer et al, 1993). The marked
increase in micronuclei in peripheral blood erythrocytes and the
increase in apoptotic cells in the duodenal crypts in mice treated
with CPT-11 was therefore expected.
Omega-3 fatty acids have been shown to slow cell proliferation
in normal tissues (Anti et al, 1994; Bartram et al, 1993; Calviello
et al, 1999; Meydani et al, 1991) thus the observed reduction in
the number of micronuclei in peripheral erythrocytes and in the
number of apoptotic ﬁgures in the duodenal crypts of mice treated
with CPT-11 and fed AAFA
TM may simply be due to slower prolif-
eration during the time of CPT-11 treatment. The fact that we
observed less apoptosis in the crypt columns of the mice yet the
number of cells in each crypt column was not changed also indi-
cates that proliferation in the intestinal mucosa was slowed due
to AAFA
TM consumption.
The reduced number of erythrocytes with micronuclei in mice
treated with CPT-11 and fed AAFA
TM may also be associated with
slowed proliferation due to a decreased demand for new erythrocytes.
In this regard, Fisher and Black (1991) reported that the erythrocytes
of mice fed 12% ﬁsh oil had higher levels of n-3 fatty acids and were
less osmotically fragile than the erythrocytes of mice fed 12% corn oil.
This could result in a longer lifespan for individual erythrocytes and a
reduced need for new erythrocytes followed by a reduced need for
proliferation of erythroblasts to maintain RBC counts in the periph-
eral blood. The marked dose dependent decrease in numbers of
polychromatic (immature) erythrocytes in mice consuming AAFA
TM
and treated with CPT-11 (Figure 1, graph 10) supports the idea that
fewer new erythrocytes were being produced to maintain the RBC
counts in the peripheral blood of AAFA
TM fed mice.
There was a dose response towards normal in mice that consumed
1 or 2% dietary AAFA
TM for: apoptotic ﬁgures in the duodenal
crypts, liver weight, WBC and RBC counts. The variance from the
dose response for 3% dietary AAFA
TM for liver weight and for
WBC counts may indicate that addition of more than 2% AAFA
TM
does not increase the effectiveness of the diet supplement for these
parameters. Two per cent AAFA
TM in the diet of the mice is equal
to 18 calories AAFA
TM per 430 calories of the diet or 4.1% of the
calories in the diet from AAFA
TM. In human terms, consumption
of 9 g of AAFA
TM per day in an 1800 calorie diet would be 81 out
of 1800 or 4.5% of the calories from AAFA
TM, 8 g per day would
equate to 72 out of 1800 or 4.0% of the calories from AAFA
TM. Thus
consumption of 8to 9 gof AAFA
TM per day by humans would equate
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Figure 2 A composite of photographs of groups of mice that were
treated as noted. The coats of the CPT-11 treated mice that did not con-
sume AAFA
TM look ‘scruffy’, i.e., the fur is not smooth and hair strands are
stuck together, especially between the scapulae. However, mice treated
with CPT-11 that consumed 1% AAFA
TM look smoother and the mice that
consumed 2 or 3% AAFA
TM did not look different from the mice that did
not receive CPT-11.
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TM diet fed the mice in this study. Anti et al (1992)
have reported that humans can safely consume 10 g ﬁsh oil per day
without ill effects while Burns et al (1999) report administration of
up to 21 g per day of an omega-3 fatty acid product. The product
used in the Burns trial contained 626 mg EPA + DHA per gram thus
the 21 g per day dose equaled 13.1 g EPA + DHA per day. Based on
the Burns phase I study, it seems that 8 or 9 g per day of AAFA
TM is a
feasible dose for humans.
Clinical trials must be conducted to determine if the beneﬁcial
effects of omega-3 fatty acid supplements seen in mice can be
translated to humans undergoing cancer therapy. Clinical trials
using a daily supplement of 8 g per day of AAFA
TM for cancer
patients undergoing chemotherapy seem warranted based on the
preclinical studies described herein and these clinical trials are
being initiated.
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